People | July 27, 2025
Granules India CEO K V Sitaram Rao resigns
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Upgrades 2025 full-year CDMO sales and margin outlook
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Subscribe To Our Newsletter & Stay Updated
